Logo image of LFST

LIFESTANCE HEALTH GROUP INC (LFST) Stock Fundamental Analysis

NASDAQ:LFST - Nasdaq - US53228F1012 - Common Stock - Currency: USD

6.62  -0.18 (-2.65%)

After market: 6.62 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LFST. LFST was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of LFST is average, but there are quite some concerns on its profitability. LFST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LFST has reported negative net income.
In the past year LFST had a positive cash flow from operations.
LFST had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: LFST reported negative operating cash flow in multiple years.
LFST Yearly Net Income VS EBIT VS OCF VS FCFLFST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

LFST has a Return On Assets (-2.71%) which is in line with its industry peers.
The Return On Equity of LFST (-3.97%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -2.71%
ROE -3.97%
ROIC N/A
ROA(3y)-7.15%
ROA(5y)-11.83%
ROE(3y)-10.4%
ROE(5y)-16.72%
ROIC(3y)N/A
ROIC(5y)N/A
LFST Yearly ROA, ROE, ROICLFST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

LFST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFST Yearly Profit, Operating, Gross MarginsLFST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

4

2. Health

2.1 Basic Checks

LFST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LFST has been increased compared to 1 year ago.
The number of shares outstanding for LFST has been increased compared to 5 years ago.
Compared to 1 year ago, LFST has a worse debt to assets ratio.
LFST Yearly Shares OutstandingLFST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
LFST Yearly Total Debt VS Total AssetsLFST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 2.35 indicates that LFST is not a great score, but indicates only limited risk for bankruptcy at the moment.
LFST has a Altman-Z score (2.35) which is comparable to the rest of the industry.
The Debt to FCF ratio of LFST is 3.35, which is a good value as it means it would take LFST, 3.35 years of fcf income to pay off all of its debts.
LFST has a better Debt to FCF ratio (3.35) than 73.53% of its industry peers.
LFST has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
LFST has a Debt to Equity ratio of 0.19. This is in the better half of the industry: LFST outperforms 70.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 3.35
Altman-Z 2.35
ROIC/WACCN/A
WACC8.77%
LFST Yearly LT Debt VS Equity VS FCFLFST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

LFST has a Current Ratio of 1.37. This is a normal value and indicates that LFST is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, LFST perfoms like the industry average, outperforming 44.12% of the companies in the same industry.
LFST has a Quick Ratio of 1.37. This is a normal value and indicates that LFST is financially healthy and should not expect problems in meeting its short term obligations.
LFST has a Quick ratio of 1.37. This is comparable to the rest of the industry: LFST outperforms 51.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
LFST Yearly Current Assets VS Current LiabilitesLFST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

LFST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.63%, which is quite impressive.
Looking at the last year, LFST shows a quite strong growth in Revenue. The Revenue has grown by 18.50% in the last year.
Measured over the past years, LFST shows a very strong growth in Revenue. The Revenue has been growing by 42.55% on average per year.
EPS 1Y (TTM)68.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
Revenue 1Y (TTM)18.5%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%15.99%

3.2 Future

Based on estimates for the next years, LFST will show a very strong growth in Earnings Per Share. The EPS will grow by 36.28% on average per year.
Based on estimates for the next years, LFST will show a quite strong growth in Revenue. The Revenue will grow by 12.39% on average per year.
EPS Next Y40.23%
EPS Next 2Y33.7%
EPS Next 3Y36.28%
EPS Next 5YN/A
Revenue Next Year14.41%
Revenue Next 2Y14.13%
Revenue Next 3Y14.7%
Revenue Next 5Y12.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LFST Yearly Revenue VS EstimatesLFST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
LFST Yearly EPS VS EstimatesLFST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LFST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFST Price Earnings VS Forward Price EarningsLFST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

62.75% of the companies in the same industry are cheaper than LFST, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LFST is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 30.04
EV/EBITDA 68.51
LFST Per share dataLFST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

LFST's earnings are expected to grow with 36.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y36.28%

More info and screens

0

5. Dividend

5.1 Amount

LFST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFESTANCE HEALTH GROUP INC

NASDAQ:LFST (5/5/2025, 8:23:15 PM)

After market: 6.62 0 (0%)

6.62

-0.18 (-2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-07 2025-05-07/bmo
Inst Owners35.32%
Inst Owner Change1.05%
Ins Owners6.62%
Ins Owner Change1.74%
Market Cap2.57B
Analysts80
Price Target9.01 (36.1%)
Short Float %8.1%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)57.54%
Min EPS beat(2)43.98%
Max EPS beat(2)71.11%
EPS beat(4)4
Avg EPS beat(4)40.26%
Min EPS beat(4)10.6%
Max EPS beat(4)71.11%
EPS beat(8)5
Avg EPS beat(8)-0.39%
EPS beat(12)7
Avg EPS beat(12)-1.34%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.52%
Min Revenue beat(2)1.32%
Max Revenue beat(2)1.72%
Revenue beat(4)2
Avg Revenue beat(4)0.28%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.72%
Revenue beat(8)5
Avg Revenue beat(8)0.87%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.85%
PT rev (3m)0.38%
EPS NQ rev (1m)1.78%
EPS NQ rev (3m)-57.15%
EPS NY rev (1m)4.66%
EPS NY rev (3m)23.47%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-1.98%
Revenue NY rev (1m)-0.14%
Revenue NY rev (3m)1.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.06
P/FCF 30.04
P/OCF 24
P/B 1.78
P/tB N/A
EV/EBITDA 68.51
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)0.22
FCFY3.33%
OCF(TTM)0.28
OCFY4.17%
SpS3.22
BVpS3.72
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.71%
ROE -3.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 6.85%
ROA(3y)-7.15%
ROA(5y)-11.83%
ROE(3y)-10.4%
ROE(5y)-16.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 3.35
Debt/EBITDA 7.08
Cap/Depr 30.4%
Cap/Sales 1.72%
Interest Coverage N/A
Cash Conversion 271.48%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z 2.35
F-Score7
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)65.1%
Cap/Depr(5y)98.49%
Cap/Sales(3y)4.93%
Cap/Sales(5y)7.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
EPS Next Y40.23%
EPS Next 2Y33.7%
EPS Next 3Y36.28%
EPS Next 5YN/A
Revenue 1Y (TTM)18.5%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%15.99%
Revenue Next Year14.41%
Revenue Next 2Y14.13%
Revenue Next 3Y14.7%
Revenue Next 5Y12.39%
EBIT growth 1Y83.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year428.75%
EBIT Next 3Y97.42%
EBIT Next 5YN/A
FCF growth 1Y249.28%
FCF growth 3YN/A
FCF growth 5Y99.09%
OCF growth 1Y735.28%
OCF growth 3Y124.97%
OCF growth 5Y44.46%